SCHEMBL2865389

SCHEMBL2865389

COc1ccc(C)c(-n2nc3c(c2N)c(=O)[nH]c2cc(OCCN4CCOCC4)ccc23)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
MAOA P21397 1/20 0.48
FGFR1 P11362 2/20 0.47
PDGFRB P09619 1/20 0.47
KDR P35968 1/20 0.47
PARP1 P09874 2/20 0.44
ACHE P22303 2/20 0.44
BCHE P06276 1/20 0.44
JAK2 O60674 1/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
FGFR2 P21802 1/20 0.41
FGFR3 P22607 1/20 0.41
NPC1 O15118 1/20 0.41
CHUK O15111 2/20 0.40
INSR P06213 2/20 0.40
MAPK8 P45983 2/20 0.40
CAMKK2 Q96RR4 2/20 0.40
CHEK1 O14757 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868581 0.96 KDM4E (0.49) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2866738 0.92 MAOA (0.47) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2858247 0.92 KDM4E (0.49) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2862095 0.92 MAOA (0.47) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2864473 0.92 MAOA (0.47) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2861437 0.90 KDM4E (0.46) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2868766 0.88 KDM4E (0.51) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2870232 0.88 MAOA (0.43) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2861165 0.88 KDM4E (0.49) KDM4EMAOAFGFR1PDGFRBKDR
SCHEMBL2864995 0.86 KDM4E (0.45) KDM4EKDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KDM4E 1057/4885MAOA 2993/4885FGFR1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.